Depression and Anxiety in Long Term Coronavirus Disease COVID-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

165 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-10-01

Study Completion Date

2022-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background :

Depression and Anxiety are linked to COVID (Coronavirus Disease)-19 long-term impact through several mechanisms. The possible way is the alteration of neurotransmitter regulation from the interaction of severe acute respiratory syndrome -Coronavirus-2 (SARS-COV2) with Angiotensin-Converting Enzyme 2 (ACE2) receptor, and Dopa Decarboxylase (DDC), an enzyme that associated with the production of dopamine, serotonin, and other neurotransmitters. However, some arguments exist that depression and anxiety occur naturally due to external stressors, as the impact of public health measures, and not associated with physiological changes due to viral infection.

Objective:

1. This study aims to identify whether the patient discharged after COVID 19 treatment has significant changes in serotonin and dopamine level which might induce depression and anxiety internally and,
2. To distinguish external etiologies that might induce depression and anxiety such as social isolation and stress due to public health restriction.

Method:

A prospective longitudinal study of people with the interest exposure is COVID 19 and the primary outcome is Depression, Anxiety, and Neurotransmitter level

Hypothesis:

People with a previous infection of COVID 19 have a significant difference in neurotransmitter level over time and compared to non exposed group and a higher prevalence of anxiety and depression.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Anxiety And Depression During COVID-19 IN INDIA

NCT04369300

COVID-19

UNKNOWN

Predictors and Mechanisms of Depression and Anxiety During the COVID-19 Pandemic

NCT04442204

Depression Anxiety

UNKNOWN

Information Sources and Their Relationship to Depressive and Anxiety Symptoms During the COVID-19 Pandemic: A Network Study

NCT04444336

Depression Anxiety

UNKNOWN

Rhythm and Depression

NCT02857036

Depression

UNKNOWN NA

Functional and Metabolic Changes in the Course of Antidepressive Treatment

NCT02099630

Major Depressive Disorder

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Method :

Prospective Longitudinal study for 6 months. with both exposed and unexposed group

Target population :

A cohort of the population in multiple centers (3 centers)

Sample Size Calculation with Longitudinal study formula:

1. Effect Size: 0.15
2. Type I error: 0.05
3. Power of Study: 80%
4. Number of Group: 2
5. Repeated measurement: 3 times
6. Correlation among Repeated Measures: 0.5
7. Nonsphericity Correction: 1
8. Initial Sample size: 75

Adjusted by clustering effect:

1. Intraclass Correlation Coefficient = 0.05
2. Number of people per cluster = 25
3. Design Effect= 1 + 0.05(25-1) = 2.2
4. Total sample size = 75 x 2.2 = 165 participants

Procedure:

1. Participants will be assessed for eligibility
2. Screening for Depression, Anxiety, and Stress using Depression Anxiety Stress Scale (DASS) Questionnaire. Health-Related Quality of Life (QoL) and Pittsburgh Sleep Quality Index (PSQI)
3. Sample Collection and assessment of QoL, DASS, PSQI on the first day
4. Sample Collection and assessment of QoL, DASS, PSQI on day 60
5. Sample Collection and assessment of QoL, DASS, PSQI on day 120

Variables

1. Case Definition: Realtime Polymerase Chain Reaction (RT-PCR) and Cycle Threshold Value (CT)
2. Degree of COVID 19 Symptom-based on World Health Organization Criteria (Asymptomatic, Mild, Moderate, Severe, Critical)
3. Sociodemographic Variables (Age, Gender, Education, Income, Marital Status)
4. Sleep Quality using Pittsburgh Sleep Quality Index (PSQI)
5. Treatment of COVID: Antiviral, Antibiotic, Interleukin-6 Antagonist, Steroid, Plasma Convalescent, Ventilator, Human Intravenous Immunoglobulin, anticoagulant
6. Chronic Disease including Diabetes Mellitus, Hypertension, Chronic Kidney Disease
7. Medication that affects neurotransmitter level taken prior to recruitment.
8. History of Smoking classified by Brinkmann Index.
9. Body Mass Index
10. Complete Blood Count
11. Vaccination history

Outcome

1. Dopamine Serum
2. Serotonin Serum
3. Prevalence of Anxiety, and Depression according to Diagnostic and Statistical Manual of Mental disorders (DSM) 5

Statistical analysis Basic Analysis: Intention to Treat analysis

1. Linear Mixed Model for Neurotransmitter
2. Generalized Estimating Equation for Prevalence of Anxiety and Depression
3. Sensitivity analysis will be conducted, concerning the lost-to-follow up
4. A subgroup analysis will be conducted, particularly the participants with specific comorbidities

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19 Depression Anxiety

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Exposed with COVID 19

The participant with confirmed RT-PCR Covid 19 at the beginning of the study

Depression

Intervention Type OTHER

Any participants who develop depression symptoms according to DSM 5 criteria

Anxiety

Intervention Type OTHER

Any participants who develop anxiety symptoms according to DSM 5 criteria

Unexposed with COVID 19

The participant without confirmed RT-PCR Covid 19 at the beginning of the study until 6 month follow up period

Depression

Intervention Type OTHER

Any participants who develop depression symptoms according to DSM 5 criteria

Anxiety

Intervention Type OTHER

Any participants who develop anxiety symptoms according to DSM 5 criteria

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Depression

Any participants who develop depression symptoms according to DSM 5 criteria

Intervention Type OTHER

Anxiety

Any participants who develop anxiety symptoms according to DSM 5 criteria

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age minimum 18 years old
2. For exposed group should be confirmed with RT-PCR
3. Not being diagnosed by depression or anxiety prior to recruitment

Exclusion Criteria

1. The unexposed participants will be excluded from the unexposed group if contracted with the virus within the 6-month observation.
2. Patient falls into critical condition and it is unlikely to attend at least one follow-up measurement
3. Patient refuses to continue observation

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes